What is “Big Three Positive” Hepatitis B?
Feb 18, 2022
Source: Cainiu Health
Dr. Zhou Fang
Introduction
What is “HBV ‘Big Three Positives’”?
The term “HBV ‘Three Positives’” refers to the simultaneous presence of hepatitis B surface antigen (HBsAg), hepatitis B e-antigen (HBeAg), and hepatitis B core antibody (anti-HBc) in the body—i.e., all three serological markers test positive. When liver function tests are abnormal, this condition is diagnosed as hepatitis B with “Big Three Positives.” If liver function remains normal, the individual is classified as an asymptomatic carrier of hepatitis B virus (HBV). Patients with HBV “Big Three Positives” typically have very high levels of HBV DNA in their blood and are highly infectious.
Hepatitis B virus (HBV) is primarily transmitted via blood and bodily fluids—including semen, saliva, and vaginal secretions—all of which may contain the virus. Transmission risk is high if these fluids come into contact with broken skin. Bloodborne transmission most commonly occurs iatrogenically (e.g., during blood collection or transfusion) or among people who inject drugs and share needles or syringes.
What Is “Triple-Positive” Hepatitis B?
“Triple-positive” hepatitis B refers to the simultaneous presence of three serological markers: hepatitis B surface antigen (HBsAg), hepatitis B e-antigen (HBeAg), and hepatitis B core antibody (anti-HBc). A positive result for all three indicates active viral replication. If liver function tests are abnormal, the condition is diagnosed as “triple-positive” hepatitis B; if liver function remains normal, the individual is considered a chronic HBV carrier. Patients with triple-positive hepatitis B typically have very high levels of circulating HBV and exhibit strong infectivity. Whether treatment is required depends on the patient’s liver function, hepatic morphology and structure, and splenic morphology and structure.
The decision to initiate antiviral therapy hinges on HBV DNA levels and liver function test results. Antiviral treatment is generally recommended when serum HBV DNA exceeds 10⁴ IU/mL and alanine aminotransferase (ALT) levels are more than three times the upper limit of normal. Current first-line antiviral therapies include nucleos(t)ide analogues and pegylated interferon-alpha. Nucleos(t)ide analogues include entecavir, tenofovir disoproxil fumarate (TDF), telbivudine, adefovir dipivoxil, and lamivudine. Pegylated interferon-alpha is particularly effective in patients with elevated ALT levels and relatively low viral loads.
Dietary Recommendations for Patients with Hepatitis B and Triple-Positive Status
Patients with hepatitis B—including those with triple-positive status—must strictly abstain from alcohol in all forms (e.g., spirits, beer, wine, and other alcoholic beverages). They should follow a low-fat, light diet and avoid greasy or heavy foods to prevent overburdening the liver and exacerbating liver dysfunction. It is advisable to consume ample fresh fruits and vegetables and high-quality protein sources. Adequate rest and avoidance of fatigue are essential. Additionally, patients should avoid medications known to be hepatotoxic and undergo regular monitoring of hepatitis B–related laboratory parameters.
We hope the above information is helpful to you.
